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E radication of HCV has generally been shown to prevent the occurrence of HCC [1 , 2].  On the 
other hand,  some reports have shown that HCC devel-
ops in some patients who achieve sustained viral 
response (SVR) with interferon-ribavirin combination 
therapy and/or direct-acting antiviral agents (DAAs) 
[3 , 4].  The frequency of primary liver cancer manifest-
ing synchronously with different pathologies is very low 
[5].  Moreover,  cholangiolocellular carcinoma (CoCC) 
is rare among primary malignant liver tumors [6].
Case Report
The patient was a 75-year-old man who was referred 
to our hospital for further examination of liver tumors.  
He had a history of successful HCV eradication 3 years 
prior,  and transcatheter arterial chemoembolization 
(TACE) therapy and radiofrequency ablation (RFA) 2 
years prior,  at a different hospital.  He also had a history 
of cerebral infarction and diabetes,  but no history of 
blood transfusion or excessive alcohol intake.  His phys-
ical examination showed no abnormality.
Blood studies upon admission showed that he had 
normal liver function,  with aspartate aminotransferase 
(AST) of 28 U/l (normal range: 13-30),  alanine amino-
transferase (ALT) 16 U/l (10-42),  and gamma-glutamyl 
transpeptidase (γGTP) 23 U/l (13-64).  He did have 
mild anemia with hemoglobin 11.6 g/dl (14.0-17.5) and 
a slightly elevated HbA1c of 6.7% (4.3-5.8).  Other labs 
were normal: total bilirubin,  0.6 mg/dl (0.30-1.20);  
total protein,  8.1 g/dl (6.7-8.3); albumin,  4.4 g/dl 
(3.8-5.3); prothrombin time,  70.0% (70-130) and 1.10 
(international normalized ratio) (0.90-1.10); alpha- 
fetoprotein (AFP),  3.2 ng/ml (0-8.8); and protein- 
induced vitamin K absence or antagonist (PIVKA-II),  
32 mAU/ml (0‒40).  His indocyanine green retention 
rate at 15 minutes (ICG-R15) of 17.5 meant slight dam-
Acta Med.  Okayama,  2021
Vol.  75,  No.  2,  pp.  213-218
CopyrightⒸ 2021 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Case Report
A Case of Dual-pathology Hepatocellular Carcinoma (HCC) and  
Cholangiolocellular Carcinoma (CoCC) after Eradication of  
Hepatitis C Virus (HCV) Infection
Manabi Miyashitaa＊,  Yousuke Saragaib,  Tsuyoshi Fujimotob,  Shouichi Tanakab,   
Hideki Aokic,  and Yumiko Satod
Departments of aHepatology,  bGastroenterology,  cSurgery,  dPathology,   
National Hospital Organaization of Iwakuni Clinical Center,  Iwakuni,  Yamaguchi 740-8510,  Japan
A 75-year-old Japanese man visited our hospital for further examination of liver tumors.  He had a history of 
successful hepatitis C virus (HCV) eradication and therapy for hepatocellular carcinoma (HCC) at another hos-
pital.  Magnetic resonance imaging (MRI) revealed two tumors in the liver.  He underwent anterior inferior (S5) 
and posterior inferior (S6) subsegmentectomy of the liver.  Microscopic examination found that one tumor was 
HCC while the other was cholangiolocellular carcinoma (CoCC).
We experienced a rare case of liver cancer with two synchronous pathologies,  HCC and CoCC.
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age to his hepatic reserve.  Hepatitis B virus (HBV) 
surface antigen (HBsAg) was negative,  and HCV anti-
body (HCVAb) was positive but not detected on HCV-
RNA by nested reverse transcription polymerase chain 
reaction (RT-PCR) (Table 1).
Abdominal ultrasonography (US) showed a low- and 
high-echoic lesion 14 mm in diameter,  in the inferior 
subsegment of anterior sector (Couinaud’s segment 5:  
S5) (Fig. 1).  In the non-contrast computed tomography 
(CT) study,  the lesion was unclear,  but contrast CT 
depicted a homogeneously enhanced tumor in the early 
phase with a low-density area compared to the adjacent 
parenchyma on the late phase.  Both CT and US sug-
gested that liver had only a single lesion (Fig. 2).
However,  MRI revealed that there were two hetero-
geneous tumors in S5.  The larger one (as described 
lesion) which was unclear on T1-weighted images and 
high-intensity on T2-weighted images,  was the tumor 
identified by US and CT (Fig. 3).  But another tumor 
6 mm in diameter coexisted near the gallbladder in S5.  
This smaller tumor showed slightly low intensity on 
T1-weighted images and high intensity on T2-weighted 
images.  This smaller tumor was only detected by MRI 
(Fig. 4).
Angiographic imaging showed only one hypervas-
cular tumor stain in S5 (Fig. 5).
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Fig. 1　 Abdominal ultrasonography (US) showed a poorly demar-
cated lesion with low-echoic peripheral area and high-echoic central 
area in the anterior inferior portion of the liver.
A B
C D
Table 1　 Laboratory findings on admission
WBC 4400 /μl BUN 19.2 mg/dl
RBC 395×104 /μl CRTN 0.9 mg/dl
Hb 11.6 g/dl Uric acid 5.9 mg/dl
Ht 34.6 % Na 144 mEq/l
PLT 16.5×104 /μl K 4.7 mEq/l
PT 83.8 % Cl 106 mEq/l
CRP 0.04 mg/dl Ca 9.8 mg/dl
HDL-cho 46 mg/dl
T.Bil 0.61 mg/dl LDL-cho 138 mg/dl
D.Bil 0.07 mg/dl Triglyceride 87 mg/dl
T.P 7.5 g/dl Blood sugar 108 mg/dl
Alb 3.9 g/dl HbA1c 6.7 %
AST 28 U/l HBsAg (-)
ALT 16 U/l HCVAb (+)
ALP 420 U/l HCV-RNA n.d
γGTP 23 U/l AFP 3.2 ng/ml
LDH 220 U/l PIVKA-II 32 mAU/ml
ChE 211 U/l ICG-R15 17.5
Fig. 2　 Abdominal computed tomography (CT) 
without contrast study (A) and with contrast study 
(B-D); The non-contrast CT study showed an 
unclear lesion (A).  However,  contrast CT depicted 
a homogeneously enhanced tumor in the early 
phase (B),  and a tumor with lower density than the 
adjacent hepatic parenchyma in the delayed phase 
(D).  The liver itself looked cirrhotic.
We thought that the larger tumor was HCC and 
considered the smaller tumor a satellite nodule.  In June 
2010 the patient underwent anterior inferior (S5) and 
posterior inferior (S6) subsegmentectomy of the liver,  
together with cholecystectomy.
Macroscopically,  the resected section of the liver was 
observed to contain the larger tumor as a well- 
encapsulated whitish mass,  11 mm in diameter.  The 
smaller tumor near the gallbladder was unclear upon 
gross inspection (Fig. 6).
On microscopic examination,  the larger tumor in S5 
was found to be well-differentiated HCC (Fig. 7A),  
while the smaller tumor near the gallbladder was CoCC 
(Fig. 7B-D).  The cells of the smaller tumor had ovoid 
nuclei with few atypia and had proliferated in the anas-
tomosing pattern of small glands,  mimicking a ductular 
reaction — similar to cholangioles with a background of 
abundant fibrous stroma and hyaline tissue (Fig. 7B).  
These cells were immunohistologically positive for poly-





Fig. 5　 Angiographic imaging showed only one hypervascular 
tumor stain in S5 but did not stain the nearby gallbladder.  Hepatic 
arteries had a corkscrew appearance.
Fig. 3　 On abdominal magnetic resonance imag-
ing (MRI),  the large lesion was not observed with 
T1-weighted imaging (A) but was observed as a 
hyperintense mass on T2-weighted imaging (B) in 
the anterior inferior portion (S5) of the liver.  The 
same lesion was observed as a hyperintense mass 
in the artery phase (C) and as a hypointense mass 
in the hepatobiliary phase after the administration of 
Gd-EOB-DTPA.
Fig. 4　 On abdominal magnetic resonance imag-
ing (MRI),  the smaller lesion near the gallbladder 
that was undetected by US and CT was also not 
observed on T1-weighted imaging (A),  but was 
observed as a hyperintense mass on T2-weighted 
imaging (B).  The same lesion was observed as a 
hyperintense mass in the artery phase (C) and as a 
hypointense mass in the hepatobiliary phase after the 
administration of Gd-EOB-DTPA.
clonal CEA and CD56 (N-CAM) (Fig. 7C , D).  The liver 
parenchyma surrounding the 2 tumors showed cirrhotic 
and chronic active inflammation.  The patient’s postop-
erative course was uneventful,  and he was discharged 
on postoperative day 20.  Unfortunately,  he died of 
pneumonia 2 years later,  but with no recurrence of 
HCC or CoCC.
Discussion
Cells of CoCC resemble cholangioles in structure,  
and mimic a ductular reaction with abundant fibrous 
stroma [7].  CoCC is composed of small,  regular glan-
dular structures that are enlarged to border sheets of 
cuboidal cells with oval nuclei [7].
It is typically very difficult to diagnose CoCC.  Not 
only is the frequency of CoCC extremely rare,  but also 
the malignancy of the tumor is extremely difficult to 
identify pathologically [8].  The features that may help to 
differentiate CoCC from benign ductular reactions are 
the presence of more than one cell layer linking the 
tumoral ductular structures,  the location of tumoral 
ductules in the middle of the lobules and at the margin 
of the portal tract,  and an infiltrative pattern at the bor-
der of the lesion as well as the invasion of portal tracts 
within the tumor itself [8].  CD56 (N-CAM) is expressed 
in benign bile ductules as well as ductular structures of 
CoCC [9].  Differential diagnosis from intrahepatic 
cholangiocarcinoma (ICC) or cholangiocellular carci-
noma (CCC) is easier because ICC/CCC has a more 
malignant appearance with architectural and cytologic 
abnormalities,  and ICC/CCC is commonly negative for 
CD56 (N-CAM) [9].  In our patient,  the cells of the 
smaller tumor had ovoid nuclei with few atypia,  and 
had proliferated in the anastomosing pattern of small 
glands,  mimicking a ductular reaction with a back-
ground of abundant fibrous stroma and hyaline tissue.  
These cells were immunohistologically positive for 
polyclonal CEA [7]and CD56 (N-CAM) [9].  Hence,  we 
could diagnose CoCC but not ICC/CCC.
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Fig. 6　 Macroscopically,  the large resected tumor specimen 
appeared as a well-encapsulated whitish mass,  11 mm in diameter.  
The smaller tumor near the gallbladder was not easily visualized.
A B
C D
Fig. 7　 Microscopically,  the large lesion was well 
differentiated hepatocellular carcinoma (HCC) 
(A: Hematoxylin and eosin (H-E) stain).  The smaller 
lesion appeared as cells with ovoid nuclei,  which 
proliferated in an anastomosing pattern of small 
glands,  mimicking ductular reactions with a back-
ground of abundant fibrous stroma and hyaline tis-
sue (B: H-E stain).  These cells were immunohisto-
logically positive for polyclonal CEA (C) and CD56 
(N-CAM) (D); thus,  the histological diagnosis was 
cholangiolocellular carcinoma (CoCC).
Recently,  eradication of HCV has been shown to 
prevent the occurrence of HCC [1].  Singal et al.  
reported that achieving SVR was associated with lower 
liver-related morbidity and mortality [10].  But other 
studies showed that HCC developed in some patients 
although they achieved SVR with therapy of interferon 
and ribavirin [3].  In a study by Sanefuji et al.  compar-
ing 6 SVR with 20 non-SVR patients,  the intervals 
between the achievement of SVR and the detection of 
the initial HCC ranged from 13 to 152 months with a 
mean interval of 74 months (6.2 years) [11].  Nojiri et al.  
reported in their study that potential risk factors for 
HCC after SVR ware male gender,  advanced fibrosis,  
older age at treatment and sustained elevated ALT [12].  
Huang et al.  reported a lack of strong evidence for 
increased risk of HCC occurrence or recurrence in 
HCV-infected patients treated with DAAs,  but signifi-
cant evidence for a decline in the incidence of HCC 
occurrence after SVR [4].
The frequency of synchronous dual-pathology pri-
mary cancers in the liver is very low,  and most cases 
reported with this phenomenon had HCC and ICC/
CCC [5].  In our search of the English literature,  we 
found 6 case reports of synchronous dual-pathology 
liver cancers with HCC and CoCC [13-18].  The first 
case of CoCC was reported by Steiner and Higginson 
[6].  Recently,  several studies have postulated that 
CoCC originates with hepatic stem cells [7 , 8 , 19].  
CoCC is a very rare malignant primary hepatic tumor,  
accounting for 0.56% of primary hepatic tumors in 
Japan [19].  In an assessment of the 6 CoCC cases by 
Shiota et al.,  3 of the 6 (50%) cases were positive for 
HCVAb,  one case (16.7%) was positive for HBsAg,  and 
2 cases (33.3%) were negative for both HBsAg and 
HCVAb [19].  In a report of 24 CoCC cases checked for 
serum virus markers,  6 of 24 (25%) were positive for 
HCVAb,  one case (4.2%) was positive for HBsAg only,  
and 2 cases (8.3%) were negative for both HBsAg and 
HCVAb [7].  These findings may suggest that occur-
rence of CoCC is mainly associated with HCV infec-
tion.  Our patient was also positive for HCVAb,  but was 
not detected as such on HCV-RNA by RT-PCR.  The 
reason why MRI was the only diagnostic tool that could 
differentiate CoCC might be the slow-growing nature of 
this smaller tumor.
Unfortunately,  histopathological study of the pri-
mary liver tumor was not done before our patient 
received TACE and RFA.  Therefore,  we cannot deter-
mine the clinical details of how his synchronous dual- 
pathology hepatic cancer occurred.  We speculate that 
the primary liver tumor would be CoCC or combined 
HCC/CoCC,  and that different component cancers 
recurred synchronously in the different liver areas.
Further research is needed to clarify the frequency of 
synchronous dual-pathology HCC and CoCC cancer,  
and to investigate the frequency of CoCC occurrence 
after eradication of HCV.
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